Filing Flows › Biodesix (BDSX) › Q2 2026
Biodesix (BDSX) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 5, 2026
Biodesix (BDSX) reported revenue of $26.9M for the second quarter 2026 (Q2 2026), +34% from a year earlier and +5% from the quarter before. Operating margin was -20.1%, net loss $7.3M (27.1% of revenue).
Biodesix, Q2 2026: revenue $26.9M (+34% year over year), operating margin -20.1%, net loss $7.3M, operating cash flow −$1.6M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $26.9M | +5% | +34% |
| Operating profit | −$5.4M | — | — |
| Net earnings | −$7.3M | — | — |
| Operating cash flow | −$1.6M | — | — |
What changed
Revenue was $26.9M in Q2 2026, up 34% year over year and up 5% from the previous quarter. Diagnostic Tests was the largest line at 94% of revenue. Diagnostic Tests added $7.5M year over year (up 42%), 109% of the total change. Development Services declined 29%.
Operating costs exceeded revenue by $5.4M, an operating margin of -20.1%. Total costs grew 8% against revenue growth of 34%. The fastest-growing cost line was Other operating costs (+19%). The quarter ended with a net loss of $7.3M, narrower than the previous quarter's $7.8M loss.
Operating cash flow was −$1.6M. Non-cash charges added back $1.4M of depreciation and amortization and $820K of share-based compensation. Working capital and other items added $3.5M. Capital expenditures of $197K exceeded it, leaving free cash flow of −$1.8M.
Questions
What was Biodesix's revenue in the second quarter 2026?
Biodesix (BDSX) reported revenue of $26.9M for the second quarter 2026 (Q2 2026), +34% from a year earlier and +5% from the quarter before.
Was Biodesix profitable in the second quarter 2026?
Operating loss was $5.4M (-20.1% of revenue) and net loss $7.3M.
Source: Biodesix 10-Q on SEC EDGAR.